Achieving Multiple Myeloma Remission and What Comes Next

Remission in multiple myeloma is achievable for the majority of newly diagnosed patients, though the word means something different here than it does for many other cancers. Rather than a single cure point, myeloma remission exists on a spectrum, from partial response all the way down to no detectable cancer cells at the most sensitive laboratory tests available. Modern drug combinations push roughly 80 to 90 percent of patients into at least a complete response, and a growing body of evidence shows that the deeper the response, the longer it lasts. What happens after reaching remission, though, is just as consequential as getting there: maintenance therapy, long-term monitoring, bone protection, infection prevention, and vigilance for relapse all shape outcomes for years.

What “Remission” Actually Means in Myeloma

In most solid cancers, remission and “no evidence of disease” are treated almost interchangeably. Myeloma is different. The International Myeloma Working Group defines a ladder of response categories, from partial response through very good partial response, complete response, and stringent complete response. A complete response means no detectable abnormal protein on standard blood and urine tests and fewer than five percent plasma cells in the bone marrow. But even at that level, millions of myeloma cells can still be hiding.

That is why the field has moved toward measuring minimal residual disease. MRD testing uses either highly sensitive flow cytometry or DNA sequencing of the bone marrow to detect as few as one myeloma cell among a million normal cells. Achieving MRD-negative status offers prognostic insight that goes beyond conventional response criteria.¹ In large clinical trials, patients who reached MRD negativity had an 82 percent reduction in the risk of disease progression and an 88 percent reduction in the risk of death compared to those who remained MRD positive. Strikingly, achieving that depth of response even overcame the traditionally poor prognosis of high-risk genetic features detected at diagnosis.²

In practical terms, MRD negativity is becoming the benchmark that treatment teams aim for. It is not yet universally used to make treatment decisions outside of clinical trials, but it increasingly guides how doctors think about prognosis and whether a given regimen has done its job.

Getting There: Frontline Treatment Regimens

The path to remission typically begins with induction therapy, a combination of drugs designed to kill myeloma cells quickly and deeply. For the past several years, the backbone has been a three-drug regimen of bortezomib, lenalidomide, and dexamethasone (often abbreviated VRd). More recently, adding a fourth drug, the anti-CD38 antibody daratumumab, has become the standard for many patients.

The evidence behind this shift is strong. In the PERSEUS trial, which studied transplant-eligible patients, adding daratumumab to VRd increased the rate of complete response or better from about 70 percent to nearly 88 percent, and the rate of MRD negativity jumped from roughly 48 percent to 75 percent. At four years, about 84 percent of patients on the four-drug regimen remained free of progression, compared to 68 percent on VRd alone.³ A meta-analysis pooling data from multiple trials confirmed that daratumumab-based four-drug regimens improved both progression-free and overall survival compared to three-drug regimens in transplant-eligible patients.⁴

For patients who are older or who have health conditions that make transplant risky, the CEPHEUS trial showed that the same daratumumab-VRd combination still outperformed VRd alone. MRD negativity rates were about 61 percent versus 39 percent, and the risk of progression or death dropped by 43 percent.⁵ This means the four-drug approach benefits patients across a wide age range, not just younger or fitter individuals.

The Role of Stem Cell Transplant

For patients healthy enough to tolerate it, autologous stem cell transplant after induction therapy remains a standard step. The procedure involves collecting a patient’s own stem cells, administering high-dose chemotherapy to wipe out remaining myeloma cells in the bone marrow, and then reinfusing the stored stem cells to rebuild the blood system. A meta-analysis of trials comparing transplant to non-transplant approaches found that transplant improved the chance of complete response and cut the risk of progression roughly in half, with meaningful improvements in overall survival as well.⁶

That said, the question of whether transplant remains essential in the era of daratumumab-based regimens is an active area of research. Some ongoing trials are testing whether the deeper responses produced by four-drug induction might allow certain patients to defer or skip transplant without compromising long-term outcomes. For now, transplant-eligible patients are generally still offered the procedure, but the conversation between doctor and patient has become more nuanced.

Maintenance Therapy and How Long to Continue

Reaching remission is not the end of treatment. Most patients begin maintenance therapy, typically lenalidomide taken daily at a lower dose, to keep the cancer suppressed. The logic is straightforward: myeloma almost always harbors residual cells that can eventually regrow, and ongoing low-dose treatment delays that process. A trial of continuous versus fixed-duration lenalidomide-based therapy found that continuous treatment nearly doubled the time before the disease progressed and improved overall survival at four years (about 69 percent versus 60 percent).⁷

The harder question is how long maintenance should last. Many patients take lenalidomide indefinitely, sometimes for years, until the disease progresses or side effects become intolerable. A large randomized trial with a median follow-up of seven years compared indefinite lenalidomide maintenance to a fixed two-year course. Progression-free survival was modestly better with indefinite treatment (about 36 percent versus 30 percent at seven years), but overall survival was virtually identical, around 69 percent in both groups. Meanwhile, patients on indefinite therapy experienced substantially more side effects, including a higher rate of serious adverse events.⁸

One concern with long-term lenalidomide use is an increased risk of second primary cancers. In the Myeloma XI trial, the overall incidence of second cancers was about 7.7 percent among transplant-eligible patients on lenalidomide maintenance compared to 3.2 percent in those who were simply observed, though mortality from myeloma itself was significantly lower in the maintenance group.⁹ The seven-year trial mentioned above found a cumulative second-cancer incidence of about 11 percent with indefinite lenalidomide versus 8 percent with fixed-duration treatment.⁸ The risk is real, but the numbers are small relative to the benefit of preventing myeloma relapse, and deaths from second cancers remained low compared to deaths from progressive myeloma.⁹

For many patients, these findings mean the question is no longer “should I take maintenance” but “when is it reasonable to stop.” MRD testing may eventually help answer that: if a patient is deeply MRD negative for a sustained period, there may be a rationale for stopping maintenance, though trials specifically designed to test this approach are still underway.

Monitoring for Relapse

Once in remission, you enter a phase of regular surveillance. Blood work tracks the myeloma-related proteins, including the M-protein and serum free light chains. An abnormal free light chain ratio or a rise in involved light chains was observed in about 82 percent of patients at the time of relapse, and the changes often showed up two to four months before the disease met standard relapse criteria.¹⁰ This early warning signal gives doctors a head start in planning next steps.

Imaging plays a complementary role. Whole-body MRI and PET/CT scans can detect residual or recurring disease in the bones and soft tissues, providing information that blood tests alone miss.¹¹ This matters because a subset of relapses occur outside the bone marrow as so-called extramedullary disease, where standard blood markers may lag behind what imaging reveals.

Why Myeloma Comes Back

Despite the depth of modern remissions, relapse remains the rule rather than the exception. The biology behind this is rooted in how myeloma evolves. At diagnosis, the tumor is not a single uniform population of cells but a patchwork of genetically distinct subclones. Treatment kills the dominant clone, but minor subclones that carry different genetic features can survive and expand, eventually driving a relapse that may look and behave differently from the original disease.¹²

The bone marrow itself also shelters residual myeloma cells. Specialized niches within the marrow can push surviving cells into a dormant state, shielding them from both the immune system and chemotherapy. When conditions change, those dormant cells can reactivate and begin proliferating again.¹³ Certain features at diagnosis, including high-risk chromosomal abnormalities, high tumor burden, and poor performance status, are associated with earlier relapse.¹⁴

Newer Options When the Disease Returns

If myeloma does relapse, the treatment landscape has expanded considerably in recent years. Two classes of immunotherapy now target a protein called BCMA, which sits on the surface of myeloma cells. CAR T-cell therapies, including the FDA-approved products idecabtagene vicleucel and ciltacabtagene autoleucel, involve collecting a patient’s T cells, engineering them in a laboratory to recognize BCMA, and infusing them back. These treatments have produced deep responses in patients whose disease had stopped responding to multiple prior lines of therapy.

Bispecific antibodies offer another approach. Teclistamab, which bridges T cells to myeloma cells by binding both CD3 and BCMA, produced an overall response rate of about 63 percent in heavily pretreated patients, with roughly 39 percent achieving a complete response or better.¹⁵ Unlike CAR T-cell therapy, bispecific antibodies are given as off-the-shelf injections without the need for laboratory manufacturing, making them accessible more quickly. Both approaches carry serious side effects, including cytokine release syndrome and infections from immune suppression, but they represent a genuine shift for patients who have run out of conventional options.

Bone Health During and After Treatment

Bone disease is one of the most common and painful complications of myeloma. The cancer directly stimulates bone breakdown and suppresses new bone formation, leading to fractures, spinal compression, and chronic pain. Treatment of the myeloma itself slows this process, but bone-modifying agents are typically added on top. Bisphosphonates like zoledronic acid and the antibody denosumab both reduce the risk of skeletal complications, and denosumab has been shown to be at least as effective as zoledronic acid for preventing these events.¹⁶

Most fractures and skeletal events in myeloma cluster in the first year, but the risk does not disappear after that. Randomized studies suggest that continuing bone-modifying agents for up to four years can further reduce skeletal complications with relatively few additional side effects.¹⁷ One rare but serious side effect of long-term bisphosphonate use is osteonecrosis of the jaw, so dental health and regular check-ups matter throughout treatment.

Infection Risk and Vaccination

Infection is the leading cause of illness and death in myeloma patients, a fact that persists across every phase of the disease. The cancer itself weakens normal antibody production, and treatment further suppresses the immune system. This cumulative immune deficit means that preventing infections through vaccination, antimicrobial prophylaxis, and sometimes immunoglobulin replacement is a central part of survivorship care.

Vaccine responses, however, tend to be blunted. For pneumococcal vaccines, standard polysaccharide vaccines produce protective antibody levels in only about a third to 40 percent of patients. The conjugate vaccine performs somewhat better, with response rates up to 58 percent in the post-transplant setting, and lenalidomide maintenance does not appear to further impair vaccine effectiveness.¹⁸ The practical takeaway is that vaccination is still worthwhile, but you should not assume it has worked as well as it would in someone with a healthy immune system. Timing vaccines during remission or before transplant, when the immune system is in better shape, tends to produce stronger responses.

Peripheral Neuropathy and Quality of Life

One of the most common lasting side effects of myeloma treatment is peripheral neuropathy, a form of nerve damage that causes numbness, tingling, or pain in the hands and feet. The drugs most responsible are thalidomide and bortezomib, both of which are cornerstones (or former cornerstones) of treatment. Sensory symptoms are far more common than motor weakness, but neuropathic pain can significantly affect daily life and sometimes forces dose reductions or drug switches.¹⁹

The encouraging news is that bortezomib-related neuropathy is reversible in most patients when caught early. In the large APEX trial, about 64 percent of patients who developed at least moderate neuropathy saw improvement or full resolution, typically within a few months. Patients whose doses were adjusted promptly did better: about 68 percent improved, versus 47 percent of those whose doses were not modified.²⁰ Reporting symptoms early is crucial, and doctors who use subcutaneous rather than intravenous bortezomib see lower neuropathy rates to begin with. Preexisting conditions like diabetes or vitamin deficiencies can increase susceptibility, so addressing those risk factors before starting therapy is part of good planning.²¹

Cardiovascular Health in Long-Term Survivors

As more patients live longer with myeloma, the medical community is learning about late effects that did not get much attention when survival was shorter. Cardiovascular disease is one area where the picture has surprised researchers. A large Korean case-control study found that overall, long-term myeloma survivors actually had a lower incidence of cardiovascular events compared to a matched population without myeloma. However, there was a notable exception: patients diagnosed before age 50 had a consistently higher rate of cardiovascular problems, even years after achieving long-term survival.²² The reasons are not fully understood but may relate to the cumulative cardiovascular toxicity of treatments received at a younger age. For younger survivors especially, proactive monitoring and cardiovascular risk management with standard measures like blood pressure control and cholesterol management are worth discussing with a care team.

Disparities in Access and Outcomes

Not everyone has the same path to remission. Myeloma is roughly twice as common in Black Americans as in white Americans, and there are meaningful disparities in treatment access. Hispanic and Latino individuals, the fastest-growing demographic group in the United States, also face higher incidence rates, are diagnosed at younger ages, and are more likely to experience delays in treatment or underuse of standard and newer therapies compared to non-Hispanic white patients.²³ These gaps are not explained by biology alone. Insurance status, proximity to specialized cancer centers, clinical trial enrollment, and systemic barriers all play a role. Importantly, studies consistently show that when patients from all racial and ethnic groups receive the same treatments, survival outcomes tend to converge, which underscores that access, not inherent treatment resistance, drives most of the disparity.

The Financial and Time Burden of Ongoing Treatment

Remission does not end the demands on a patient’s time and finances. In a survey of over 250 myeloma patients, about 22 percent met criteria for significant financial toxicity, driven primarily by out-of-pocket costs and lower income levels. The time burden was even more widespread: 40 percent of patients overall met criteria for significant time toxicity, and among those on active therapy, that figure reached 82 percent. Financial strain was linked to worse mental health-related quality of life, while the time burden correlated with lower functional status.²⁴ These are not minor inconveniences. For a disease that can require years of maintenance therapy, regular blood draws, bone density monitoring, and imaging, the cumulative load of clinic visits and pharmacy runs reshapes daily life. Social work referrals, patient assistance programs, and honest conversations with your treatment team about the practical costs of different regimens are all reasonable steps to manage this reality.